Is Fate Therapeutics Stock a Good Investment?
Fate Therapeutics Investment Advice | FATE |
- Examine Fate Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Fate Therapeutics' leadership team and their track record. Good management can help Fate Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Fate Therapeutics' business and its evolving consumer preferences.
- Compare Fate Therapeutics' performance and market position to its competitors. Analyze how Fate Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Fate Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Fate Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Fate Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Fate Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Fate Therapeutics Stock
Researching Fate Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 90.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.33. Some equities with similar Price to Book (P/B) outperform the market in the long run. Fate Therapeutics recorded a loss per share of 1.64. The entity had not issued any dividends in recent years.
To determine if Fate Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Fate Therapeutics' research are outlined below:
| Fate Therapeutics generated a negative expected return over the last 90 days | |
| Fate Therapeutics has high historical volatility and very poor performance | |
| Fate Therapeutics has some characteristics of a very speculative penny stock | |
| Fate Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 13.63 M. Net Loss for the year was (186.26 M) with loss before overhead, payroll, taxes, and interest of (104.9 M). | |
| Fate Therapeutics currently holds about 568.85 M in cash with (122.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Fate Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 90.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: VALERIO THERAPEUTICSList of the Board Members Positions Held in Other Companies as of March 19, 2025 |
Fate Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Fate Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Fate Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Fate Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Fate Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-05-15 | 2017-03-31 | -0.2 | -0.24 | -0.04 | 20 | ||
2016-05-09 | 2016-03-31 | -0.25 | -0.29 | -0.04 | 16 | ||
2021-05-05 | 2021-03-31 | -0.43 | -0.48 | -0.05 | 11 | ||
2020-05-11 | 2020-03-31 | -0.39 | -0.44 | -0.05 | 12 | ||
2018-08-06 | 2018-06-30 | -0.32 | -0.37 | -0.05 | 15 | ||
2018-05-10 | 2018-03-31 | -0.22 | -0.27 | -0.05 | 22 | ||
2018-03-05 | 2017-12-31 | -0.24 | -0.29 | -0.05 | 20 | ||
2019-05-07 | 2019-03-31 | -0.24 | -0.3 | -0.06 | 25 |
Know Fate Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Fate Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Fate Therapeutics backward and forwards among themselves. Fate Therapeutics' institutional investor refers to the entity that pools money to purchase Fate Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | |||
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 2.8 M | |
| Goldman Sachs Group Inc | 2024-12-31 | 2.5 M | |
| Vestal Point Capital Lp | 2024-12-31 | 2.5 M | |
| State Street Corp | 2024-12-31 | 2.2 M | |
| Geode Capital Management, Llc | 2024-12-31 | 2.2 M | |
| Tang Capital Management Llc | 2024-12-31 | 1.9 M | |
| Orbimed Advisors, Llc | 2024-12-31 | 1.7 M | |
| Jpmorgan Chase & Co | 2024-12-31 | 1.7 M | |
| Jacobs Levy Equity Management, Inc. | 2024-12-31 | 1.6 M | |
| Redmile Group, Llc | 2024-12-31 | 12.9 M | |
| Blackrock Inc | 2024-12-31 | 10.9 M |
Fate Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 103.78 M.Market Cap |
|
Fate Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.52) | (0.55) | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | (0.58) | (0.61) |
Determining Fate Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Fate Therapeutics is a good buy. For example, gross profit margin measures Fate Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Fate Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Fate Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Fate Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Fate Therapeutics' management manipulating its earnings.
Evaluate Fate Therapeutics' management efficiency
Fate Therapeutics has return on total asset (ROA) of (0.2581) % which means that it has lost $0.2581 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5421) %, meaning that it created substantial loss on money invested by shareholders. Fate Therapeutics' management efficiency ratios could be used to measure how well Fate Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of March 21, 2025, Return On Tangible Assets is expected to decline to -0.44. In addition to that, Return On Capital Employed is expected to decline to -0.55. At present, Fate Therapeutics' Debt To Assets are projected to slightly decrease based on the last few years of reporting.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.80 | 1.58 | |
| Tangible Book Value Per Share | 2.80 | 1.58 | |
| Enterprise Value Over EBITDA | (1.34) | (1.41) | |
| Price Book Value Ratio | 0.59 | 0.56 | |
| Enterprise Value Multiple | (1.34) | (1.41) | |
| Price Fair Value | 0.59 | 0.56 | |
| Enterprise Value | 236.8 M | 225 M |
Understanding the operational decisions made by Fate Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 2.264 |
Basic technical analysis of Fate Stock
As of the 21st of March, Fate Therapeutics shows the Mean Deviation of 4.8, standard deviation of 6.02, and Variance of 36.19. Fate Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Fate Therapeutics market risk adjusted performance, variance, as well as the relationship between the Variance and value at risk to decide if Fate Therapeutics is priced favorably, providing market reflects its regular price of 0.91 per share. Given that Fate Therapeutics is a hitting penny stock territory we advise to closely look at its jensen alpha.Fate Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fate Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fate Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Fate Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Fate Therapeutics' Outstanding Corporate Bonds
Fate Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Fate Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Fate bonds can be classified according to their maturity, which is the date when Fate Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand Fate Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Fate Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.16) | |||
| Market Risk Adjusted Performance | (0.55) | |||
| Mean Deviation | 4.8 | |||
| Coefficient Of Variation | (529.36) | |||
| Standard Deviation | 6.02 | |||
| Variance | 36.19 | |||
| Information Ratio | (0.18) | |||
| Jensen Alpha | (0.99) | |||
| Total Risk Alpha | (0.64) | |||
| Treynor Ratio | (0.56) | |||
| Maximum Drawdown | 22.21 | |||
| Value At Risk | (10.11) | |||
| Potential Upside | 9.29 | |||
| Skewness | 0.3328 | |||
| Kurtosis | (0.17) |
| Risk Adjusted Performance | (0.16) | |||
| Market Risk Adjusted Performance | (0.55) | |||
| Mean Deviation | 4.8 | |||
| Coefficient Of Variation | (529.36) | |||
| Standard Deviation | 6.02 | |||
| Variance | 36.19 | |||
| Information Ratio | (0.18) | |||
| Jensen Alpha | (0.99) | |||
| Total Risk Alpha | (0.64) | |||
| Treynor Ratio | (0.56) | |||
| Maximum Drawdown | 22.21 | |||
| Value At Risk | (10.11) | |||
| Potential Upside | 9.29 | |||
| Skewness | 0.3328 | |||
| Kurtosis | (0.17) |
Consider Fate Therapeutics' intraday indicators
Fate Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Fate Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Fate Therapeutics time-series forecasting models is one of many Fate Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Fate Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Fate Stock media impact
Far too much social signal, news, headlines, and media speculation about Fate Therapeutics that are available to investors today. That information is available publicly through Fate media outlets and privately through word of mouth or via Fate internal channels. However, regardless of the origin, that massive amount of Fate data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Fate Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Fate Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Fate Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Fate Therapeutics alpha.
Fate Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Fate Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Fate Therapeutics Historical Investor Sentiment
Investor biases related to Fate Therapeutics' public news can be used to forecast risks associated with an investment in Fate. The trend in average sentiment can be used to explain how an investor holding Fate can time the market purely based on public headlines and social activities around Fate Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Fate Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Fate Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Fate Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Fate Therapeutics.
Fate Therapeutics Corporate Management
| Barbara Hickingbottom | Senior Development | Profile | |
| Tunde Babalola | Senior Operations | Profile | |
| Andrew Henry | Senior Operations | Profile | |
| Jessica Francis | Vice Operations | Profile | |
| YuWaye MD | Chief Officer | Profile | |
| Cindy Tahl | General Secretary | Profile | |
| Edward III | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Revenue Per Share | Quarterly Revenue Growth 0.11 | Return On Assets | Return On Equity |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Fate Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.